Bifogade filer
PDF
Kalender
| Est. tid* | ||
| 2026-10-22 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-16 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-06-02 | N/A | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2026-06-01 | N/A | Årsstämma |
| 2026-04-23 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-11 | - | Bokslutskommuniké 2025 |
| 2025-10-30 | - | Kvartalsrapport 2025-Q3 |
| 2025-09-02 | - | Extra Bolagsstämma 2025 |
| 2025-07-17 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | - | Årsstämma |
| 2025-06-05 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-10-17 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2024-06-27 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-15 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2023-06-14 | - | Årsstämma |
| 2023-04-20 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-20 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2022-06-16 | - | Årsstämma |
| 2022-04-21 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2020-06-23 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-01 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2018-05-29 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-12-22 | - | Extra Bolagsstämma 2017 |
| 2017-11-14 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-20 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-11-21 | - | Extra Bolagsstämma 2016 |
| 2016-11-09 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-21 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | - | Årsstämma |
| 2016-04-28 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-10-28 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-17 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2015-04-16 | - | Årsstämma |
| 2015-04-16 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-07-25 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2014-06-03 | - | Årsstämma |
| 2014-03-05 | - | Extra Bolagsstämma 2014 |
| 2014-02-05 | - | Bokslutskommuniké 2013 |
| 2013-07-25 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2013-05-06 | - | Årsstämma |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-09-28 | - | Kapitalmarknadsdag 2012 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-14 | - | Årsstämma |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2012-01-09 | - | Extra Bolagsstämma 2011 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Årsstämma |
| 2011-05-06 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2010-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2010-02-10 | - | Bokslutskommuniké 2009 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-05-12 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | X-dag ordinarie utdelning HNSA 0.00 SEK |
| 2009-04-29 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will also be attending the event.
If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Leerink Global Healthcare Conference, Hansa Biopharma Fireside Chat
Date, Time, and Place: Monday 9 March, 13:40 PM EDT, Miami, Florida.
Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma
Webcast: Hansa Biopharma AB (HNSA-SE)
--- ENDS ---
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.